IL33 and neoplasm: The co-administration of IL-33 and PD-1 blockade demonstrates an inhibitory effect on tumor growth, accompanied by an augmented presence of intra-tumoral ILC2s, particularly the mILC2s phenotype (ST2+KLRG+ ILC2s).